Aflibercept ophthalmic solution: Phase III started

Last month, Bayer's Bayer HealthCare unit began the double-blind, international Phase III VIVID-DME trial to compare 2 mg intravitreal VEGF Trap-eye given monthly or every 2 months following a monthly...